Cargando…
Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients
BACKGROUND: Few studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist. AIM: To describe the tolerance and efficacy of BT and APR in moderate-to-severe psoriasis in patients with a histo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275167/ https://www.ncbi.nlm.nih.gov/pubmed/34267533 http://dx.doi.org/10.2147/CCID.S320098 |
_version_ | 1783721677338705920 |
---|---|
author | Cohen-Sors, Raphaella Fougerousse, Anne-Claire Reguiai, Ziad Maccari, Francois Mahé, Emmanuel Delaunay, Juliette Roussel, Aude de la Breteque, Maud Amy Cottencin, Caroline Bertolotti, Antoine Kemp, Hélène Chaby, Guillaume |
author_facet | Cohen-Sors, Raphaella Fougerousse, Anne-Claire Reguiai, Ziad Maccari, Francois Mahé, Emmanuel Delaunay, Juliette Roussel, Aude de la Breteque, Maud Amy Cottencin, Caroline Bertolotti, Antoine Kemp, Hélène Chaby, Guillaume |
author_sort | Cohen-Sors, Raphaella |
collection | PubMed |
description | BACKGROUND: Few studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist. AIM: To describe the tolerance and efficacy of BT and APR in moderate-to-severe psoriasis in patients with a history of in-remission or evolving HM. METHODOLOGY: A retrospective, multicenter chart review of the tolerance and efficacy of BT or APR in patients with moderate-to-severe psoriasis and a clinical history of in-remission or evolving HM. RESULTS: Twenty-one patients with severe psoriasis and a history of HM were included in France by the GEM Resopso study group. Of the 16 patients treated with one or more BT lines, none showed recurrence of their HM which was considered as stable or in remission, and only 2 patients showed an evolution of their HM which had been considered as stable at the beginning of treatment. In the 10 patients treated with APR, the HM of one patient who also received BT worsened. The 3 evolutions did not impact the treatment with BT or APR. Tolerance was very satisfactory, with a low occurrence of infections. Regarding efficacy, only one patient treated with APR did not achieve any notable clinical improvement. CONCLUSION: Despite supportive data regarding tolerance, the heterogeneity of the analyzed population and limited available data, BT and APR should be used with caution in this patient population and investigations on larger cohorts should be conducted to further assess their tolerance in this patient population. |
format | Online Article Text |
id | pubmed-8275167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82751672021-07-14 Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients Cohen-Sors, Raphaella Fougerousse, Anne-Claire Reguiai, Ziad Maccari, Francois Mahé, Emmanuel Delaunay, Juliette Roussel, Aude de la Breteque, Maud Amy Cottencin, Caroline Bertolotti, Antoine Kemp, Hélène Chaby, Guillaume Clin Cosmet Investig Dermatol Original Research BACKGROUND: Few studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist. AIM: To describe the tolerance and efficacy of BT and APR in moderate-to-severe psoriasis in patients with a history of in-remission or evolving HM. METHODOLOGY: A retrospective, multicenter chart review of the tolerance and efficacy of BT or APR in patients with moderate-to-severe psoriasis and a clinical history of in-remission or evolving HM. RESULTS: Twenty-one patients with severe psoriasis and a history of HM were included in France by the GEM Resopso study group. Of the 16 patients treated with one or more BT lines, none showed recurrence of their HM which was considered as stable or in remission, and only 2 patients showed an evolution of their HM which had been considered as stable at the beginning of treatment. In the 10 patients treated with APR, the HM of one patient who also received BT worsened. The 3 evolutions did not impact the treatment with BT or APR. Tolerance was very satisfactory, with a low occurrence of infections. Regarding efficacy, only one patient treated with APR did not achieve any notable clinical improvement. CONCLUSION: Despite supportive data regarding tolerance, the heterogeneity of the analyzed population and limited available data, BT and APR should be used with caution in this patient population and investigations on larger cohorts should be conducted to further assess their tolerance in this patient population. Dove 2021-07-08 /pmc/articles/PMC8275167/ /pubmed/34267533 http://dx.doi.org/10.2147/CCID.S320098 Text en © 2021 Cohen-Sors et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Cohen-Sors, Raphaella Fougerousse, Anne-Claire Reguiai, Ziad Maccari, Francois Mahé, Emmanuel Delaunay, Juliette Roussel, Aude de la Breteque, Maud Amy Cottencin, Caroline Bertolotti, Antoine Kemp, Hélène Chaby, Guillaume Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title | Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title_full | Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title_fullStr | Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title_full_unstemmed | Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title_short | Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients |
title_sort | biological therapies or apremilast in the treatment of psoriasis in patients with a history of hematologic malignancy: results from a retrospective study in 21 patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275167/ https://www.ncbi.nlm.nih.gov/pubmed/34267533 http://dx.doi.org/10.2147/CCID.S320098 |
work_keys_str_mv | AT cohensorsraphaella biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT fougerousseanneclaire biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT reguiaiziad biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT maccarifrancois biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT maheemmanuel biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT delaunayjuliette biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT rousselaude biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT delabretequemaudamy biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT cottencincaroline biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT bertolottiantoine biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT kemphelene biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients AT chabyguillaume biologicaltherapiesorapremilastinthetreatmentofpsoriasisinpatientswithahistoryofhematologicmalignancyresultsfromaretrospectivestudyin21patients |